Compare, Analyse Natco Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NATCO PHARMA   MYLAN
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
MYLAN
Dec-18
NATCO PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,0803,398-   
Low Rs6711,870-   
Sales per share (Unadj.) Rs592.11,563.6-  
Earnings per share (Unadj.) Rs188.442.5-  
Cash flow per share (Unadj.) Rs206.3335.2-  
Dividends per share (Unadj.) Rs8.250-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs833.61,691.6-  
Shares outstanding (eoy) m36.90514.50-   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.51.7 87.8%   
Avg P/E ratio x4.662.0 7.5%  
P/CF ratio (eoy) x4.27.9 54.0%  
Price / Book Value ratio x1.11.6 67.5%  
Dividend payout %4.40-   
Avg Mkt Cap Rs m32,3111,355,343 2.4%   
No. of employees `0004.835.0 13.8%   
Total wages/salary Rs m3,2560-   
Avg. sales/employee Rs Th4,522.522,985.5 19.7%   
Avg. wages/employee Rs Th674.00-   
Avg. net profit/employee Rs Th1,439.0624.2 230.6%   
INCOME DATA
Net Sales Rs m21,848804,494 2.7%  
Other income Rs m4040-   
Total revenues Rs m22,252804,494 2.8%   
Gross profit Rs m9,284208,173 4.5%  
Depreciation Rs m662150,633 0.4%   
Interest Rs m15438,693 0.4%   
Profit before tax Rs m8,87218,847 47.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,920-2,998 -64.0%   
Profit after tax Rs m6,95221,845 31.8%  
Gross profit margin %42.525.9 164.2%  
Effective tax rate %21.6-15.9 -136.0%   
Net profit margin %31.82.7 1,171.8%  
BALANCE SHEET DATA
Current assets Rs m21,307449,229 4.7%   
Current liabilities Rs m5,920327,537 1.8%   
Net working cap to sales %70.415.1 465.6%  
Current ratio x3.61.4 262.4%  
Inventory Days Days7384 87.6%  
Debtors Days Days10793 114.1%  
Net fixed assets Rs m14,986156,059 9.6%   
Share capital Rs m369428 86.1%   
"Free" reserves Rs m30,3530-   
Net worth Rs m30,760870,315 3.5%   
Long term debt Rs m0939,350 0.0%   
Total assets Rs m37,1512,334,524 1.6%  
Interest coverage x58.61.5 3,941.3%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x0.60.3 170.7%   
Return on assets %19.12.6 737.6%  
Return on equity %22.62.5 900.4%  
Return on capital %29.33.2 922.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m7,3430-   
CASH FLOW
From Operations Rs m4,636167,174 2.8%  
From Investments Rs m-11,155-86,410 12.9%  
From Financial Activity Rs m6,509-77,879 -8.4%  
Net Cashflow Rs m-181,385 -1.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.39 Rs / USD

Compare NATCO PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare NATCO PHARMA With: ALEMBIC PHARMA  UNICHEM LAB  PLETHICO PHARMA  AJANTA PHARMA  FRESENIUS KABI ONCO.  



Today's Market

Sensex Ends above 39,000-Mark; Automobile and Banking Stocks Witness Buying(Closing)

Extending gains to the fifth day, Indian share markets rose sharply during the afternoon session and ended on a strong note.

Related Views On News

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound (Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound? (The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

The One Stock I Like in this Market (The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Two Stocks to Buy in the Great Indian Festival (Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

5 Smart Money Stocks to Profit from the Market Rebound (The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Oct 17, 2019 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS